美国每200例房颤消融就死亡1人!JACC研究:合并心衰的患者死亡风险高

2020-01-19 xujing 中国循环杂志

美国一项2010~2015年间入选60203例的全国性研究显示,每200例房颤射频消融术后,就有1人死亡,大多数死亡发生在30天再入院期间。有手术并发症、心力衰竭和医院房颤消融量少是早期死亡率的预测因素。导管消融术是治疗房颤的一种越来越常用的治疗策略,在许多重要的临床试验中,如CASTLE-AF和CABANA都显示了其有效性和安全性。研究发现,从2010年到2015年,消融后早期死亡率从0.25%

美国一项2010~2015年间入选60203例的全国性研究显示,每200例房颤射频消融术后,就有1人死亡,大多数死亡发生在30天再入院期间。有手术并发症、心力衰竭和医院房颤消融量少是早期死亡率的预测因素。



导管消融术是治疗房颤的一种越来越常用的治疗策略,在许多重要的临床试验中,如CASTLE-AF和CABANA都显示了其有效性和安全性。

研究发现,从2010年到2015年,消融后早期死亡率从0.25%上升到1.35%。

消融至死亡的中位时间为11.6天。

研究显示,高龄、合并冠心病、慢性心力衰竭和肺病或肾脏疾病的患者术后死亡风险较高。

在调整年龄和合并症后,有手术并发症或在手术量低的中心(年消融手术量<21例的医院)接受房颤消融治疗的患者更有可能在房颤消融后早期死亡。

研究者强调,及时处理术后并发症和心衰是降低房颤消融术后死亡率的关键。

来源:Edward P Cheng, et al. Risk of Mortality Following Catheter Ablation of Atrial Fibrillation. J Am Coll Cardiol, 74 (18): 2254-2264.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854639, encodeId=b973185463951, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 31 03:59:00 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079098, encodeId=32ec20e909821, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Dec 12 00:59:00 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983650, encodeId=b46e1983650dd, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 14 05:59:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255942, encodeId=1fc21255942cf, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326467, encodeId=ffd0132646e25, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421804, encodeId=53f9142180421, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031214, encodeId=7bb71031214fa, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Jan 20 02:59:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-12-31 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854639, encodeId=b973185463951, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 31 03:59:00 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079098, encodeId=32ec20e909821, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Dec 12 00:59:00 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983650, encodeId=b46e1983650dd, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 14 05:59:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255942, encodeId=1fc21255942cf, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326467, encodeId=ffd0132646e25, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421804, encodeId=53f9142180421, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031214, encodeId=7bb71031214fa, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Jan 20 02:59:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854639, encodeId=b973185463951, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 31 03:59:00 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079098, encodeId=32ec20e909821, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Dec 12 00:59:00 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983650, encodeId=b46e1983650dd, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 14 05:59:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255942, encodeId=1fc21255942cf, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326467, encodeId=ffd0132646e25, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421804, encodeId=53f9142180421, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031214, encodeId=7bb71031214fa, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Jan 20 02:59:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854639, encodeId=b973185463951, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 31 03:59:00 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079098, encodeId=32ec20e909821, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Dec 12 00:59:00 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983650, encodeId=b46e1983650dd, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 14 05:59:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255942, encodeId=1fc21255942cf, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326467, encodeId=ffd0132646e25, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421804, encodeId=53f9142180421, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031214, encodeId=7bb71031214fa, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Jan 20 02:59:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854639, encodeId=b973185463951, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 31 03:59:00 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079098, encodeId=32ec20e909821, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Dec 12 00:59:00 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983650, encodeId=b46e1983650dd, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 14 05:59:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255942, encodeId=1fc21255942cf, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326467, encodeId=ffd0132646e25, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421804, encodeId=53f9142180421, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031214, encodeId=7bb71031214fa, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Jan 20 02:59:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1854639, encodeId=b973185463951, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 31 03:59:00 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079098, encodeId=32ec20e909821, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Dec 12 00:59:00 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983650, encodeId=b46e1983650dd, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 14 05:59:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255942, encodeId=1fc21255942cf, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326467, encodeId=ffd0132646e25, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421804, encodeId=53f9142180421, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031214, encodeId=7bb71031214fa, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Jan 20 02:59:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1854639, encodeId=b973185463951, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 31 03:59:00 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079098, encodeId=32ec20e909821, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Dec 12 00:59:00 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983650, encodeId=b46e1983650dd, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Dec 14 05:59:00 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255942, encodeId=1fc21255942cf, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326467, encodeId=ffd0132646e25, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421804, encodeId=53f9142180421, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Tue Jan 21 14:59:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031214, encodeId=7bb71031214fa, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Jan 20 02:59:00 CST 2020, time=2020-01-20, status=1, ipAttribution=)]
    2020-01-20 心介

    房颤,临床上碰到很多哦

    0

相关资讯

新英格兰医学杂志病例:房颤患者皮肤变色,原来是因这种药

一位房颤并合并高血压的81岁男子,摔倒后急诊就诊。体格检查时发现,患者面部有蓝色和灰色色素沉着,鼻部、脸部和前额均变色。图1 患者面部的蓝色和灰色色素沉着患者跌倒后无受伤,自称这种皮肤变色存在已久。心电图显示有房颤,心率68次/min。服用胺碘酮治疗已有15年。同时服用的药物还要阿哌沙班、雷米普利、比索洛尔、氨氯地平。色素沉着是胺碘酮罕见的不良反应,或会随着药物的停用而减轻。跌倒可归因于体位性低血

Circulation:房颤患者服用NSAIDs和抗凝药对出血风险和心血管预后的影响

服用非甾体抗炎药(NSAIDs)与口服抗凝剂与出血风险增加有关。本研究对服用NSAIDs和阿哌沙班或华法林的房颤患者的出血风险和主要心血管预后进行评估。ARISTOTLE试验(阿哌沙班用于降低房颤患者的卒中和其他血栓栓塞事件,19201位受试者)对比阿哌沙班和华法林用于房颤患者的卒中风险增加情况。排除重度肝肾疾病的患者,共17423位被纳入分析。根据NSAIDs使用情况分层(一直使用、中间使用、一

NEJM :戒酒有助于降低房颤复发风险

研究认为,戒酒可减少常饮酒者房颤复发风险

戒酒可防房颤复发!澳大利亚随机对照研究:还可减体重和降血压

已有研究证实,过量饮酒与房颤发生和心房不良重构密切相关。《新英格兰医学杂志》发表的一项来自澳大利亚的多中心、前瞻性、开放标签、随机、对照研究提示,对于经常饮酒的房颤患者来说,戒酒可以减少房颤发作。研究者指出,经常饮酒是房颤的一个潜在可控危险因素,戒酒可以减轻房颤负荷和减少房颤复发。戒酒减轻房颤负荷的机制可能是多方面的,与改善自主神经调节功能、减轻心脏炎症、改善心房重构等有关。另外,每克酒精含有7

Heart:房颤患者肾功能下降与口服抗凝药物剂量减少

由此可见,在美国,约有四分之一的AF患者在2年的随访中,随着时间的推移,CrCl下降>20%。约有3.7%的服用NOAC治疗的患者符合减少剂量的指导标准,但其中只有20.1%的患者实际减少了用药剂量。

过度疲劳和情绪不稳定者要小心!美国研究称:心梗和房颤风险增加

据欧洲预防心脏病学杂志发表的社区动脉粥样硬化风险研究(ARIC研究)最新发现,经常感到过度疲劳、情绪低落和易怒的人发生心房颤动的风险增加,心血管病事件的风险也增加。有这些症状的的人患的是倦怠综合征,通常是由工作或家庭事务带来的长期而巨大压力引起的过度疲劳。可用问卷对倦怠综合征进行诊断。研究发现,倦怠综合征者的房颤发生风险增加20%。之前该研究组还发现,有倦怠综合征的居民,发生心梗和致命性心血管事件